

Special Issue

Therapeutic Potential of Cannabinoid Receptors Type 1 and 2—Novel Insights for Enhancing the Chance of Clinical Success

Message from the Guest Editor

The endocannabinoid system (ECS) is an important lipid signaling system, and is involved in mediating key processes of central and peripheral diseases. The ECS's key elements include lipid signaling molecules termed 'endocannabinoids', their respective receptors, biosynthetic as well as hydrolytic enzymes, and transporters. In particular, cannabinoid receptor type 1 (CB1R) and type 2 (CB2R) hold great therapeutic potential. Recent developments, including the generation of CB1R and CB2R 3D structures, the identification of allosteric binding pockets, the synthesis of organ-system-selective ligands, a better understanding of biased signaling, and mechanisms of action, could facilitate the design of next-generation drugs, thus, unlocking the receptors' full therapeutic potential. In this Special Issue of *Pharmaceuticals*, authors are invited to submit original and review articles covering preclinical and clinical findings enhancing the chance of clinical success of CB1R and CB2R therapies. The proposed topics can cover novel ligands, chemical probes, and mechanistic, translational and biomarker in vitro and in vivo studies.

Guest Editor

Dr. Uwe M. Grether

Medicinal Chemistry, F. Hoffmann-La Roche AG, Basel, Switzerland

Deadline for manuscript submissions

closed (28 February 2025)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/155494

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)